Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.76 USD
Change Today +0.06 / 1.62%
Volume 1.6K
BONE On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

xtant medical holdings inc (BONE) Snapshot

Open
$3.70
Previous Close
$3.70
Day High
$3.76
Day Low
$3.55
52 Week High
09/16/14 - $5.71
52 Week Low
11/20/14 - $2.19
Market Cap
44.2M
Average Volume 10 Days
9.4K
EPS TTM
$-1.63
Shares Outstanding
11.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XTANT MEDICAL HOLDINGS INC (BONE)

Related News

No related news articles were found.

xtant medical holdings inc (BONE) Related Businessweek News

No Related Businessweek News Found

xtant medical holdings inc (BONE) Details

Xtant Medical Holdings, Inc. develops, manufactures, and markets biologics products in the United States and internationally. The company offers products that are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, neurosurgery, and regeneration in knee and other joint surgeries. Its products include OsteoSponge, which provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC, a subchondral bone void filler; OsteoSelect DBM putty, an osteoinductive product used by surgeons as a bone void filler in the extremities and pelvis; and OsteoWrap that wraps around non-union fractures to assist with fusion, and could be used in conjunction with a hardware plate system. The company also provides OsteoLock and BacFast HD facet stabilization dowels used to augment spinal procedures; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and hMatrix dermal scaffold, which promotes cellular ingrowth, tissue vascularization, and regeneration. In addition, it processes and sells sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company’s products include 3Demin cortical fibers, 3Demin boats, and 3Demin strips made from cortical bone and primarily used in spine procedures. It markets its products through direct sales, as well as through distributor relationships. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

148 Employees
Last Reported Date: 03/18/15

xtant medical holdings inc (BONE) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $500.2K
President
Total Annual Compensation: $153.8K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $350.0K
Chief Operating Officer
Total Annual Compensation: $338.6K
Chief Scientific Officer
Total Annual Compensation: $271.1K
Compensation as of Fiscal Year 2014.

xtant medical holdings inc (BONE) Key Developments

Xtant Medical Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for Second Half and Full Year 2015 and Full Year 2016

Xtant Medical Holdings, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $9,892,615 against $8,883,932 a year ago. Loss from operations was $1,383,291 against $1,332,009 a year ago. Net loss from operations before income taxes was $2,895,977 against $1,900,430 a year ago. Net loss was $2,895,977 or $0.41 per basic and diluted share against $1,900,430 or $0.35 per basic and diluted share a year ago. LBITDA was $918,182 million compared $769,645 a year ago. The higher revenues reflect increased penetration of targeted markets and an increase in internal and external sales resources compared to prior periods. The increased loss primarily reflects increased sales and marketing expenses associated with the company's ongoing execution of its strategy to increase and enhance field sales assets to drive future revenue growth. For the six months, the company reported total revenue of $19,395,729 against $17,796,902 a year ago. Loss from operations was $3,115,960 against $2,524,010 a year ago. Net loss from operations before income taxes was $7,072,781 against $6,040,685 a year ago. Net loss was $7,072,781 or $1.02 per basic and diluted share against $6,040,685 or $1.11 per basic and diluted share a year ago. Net cash used in operating activities was $4,090,237 against $3,870,558 a year ago. Purchases of property and equipment and intangible assets were $70,441 against $115,202 a year ago. LBITDA was $2,224,766 compared to $1,484,829 in the prior year. Pro forma Loss from operations was $3,379,962 compared to $1,568,487 in the prior year. Pro Forma EBITDA was $1,192,215 compared to $2,463,555 in the prior year. For the second half of 2015, the company has updated its guidance to reflect its recent acquisition of X-spine. The company is providing second half 2015 revenue guidance for the combined company in the range of $43 million to $46 million and second half 2015 EBITDA guidance within the range of $2.0 million and $2.5 million, excluding one time, non-recurring transaction expenses. For the full year 2015, the company's gross margins are expected to 64% to 66%. EBITDA to be between $3.2 million and $3.7 million For full year 2016, the company is projecting revenues in the range of $100 million to $105 million and EBITDA of approximately $7.0 to $9.0 million. Gross margins are expected to 65% to 67%. EBITDA to be between $7 million and $9 million.

Bacterin International Holdings, Inc. to Report Q2, 2015 Results on Aug 12, 2015

Bacterin International Holdings, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 12, 2015

Bacterin International Holdings, Inc., Q2 2015 Earnings Call, Aug 13, 2015

Bacterin International Holdings, Inc., Q2 2015 Earnings Call, Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BONE:US $3.76 USD +0.06

BONE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alphatec Holdings Inc $0.54 USD -0.03
Exactech Inc $18.64 USD +0.37
RTI Surgical Inc $6.33 USD +0.04
SeaSpine Holdings Corp $14.55 USD -0.47
Wright Medical Group Inc $23.28 USD -0.15
View Industry Companies
 

Industry Analysis

BONE

Industry Average

Valuation BONE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XTANT MEDICAL HOLDINGS INC, please visit www.bacterin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.